Rockland and LIMR Expand Licensing and Commercialization Relationship
News Oct 30, 2012
Rockland Immunochemicals Inc., has announced the expansion of a licensing and commercialization relationship with Lankenau Institute for Medical Research (LIMR) through its business development subsidiary LIMR Development, Inc. (LDI). Instrumental in advancing this relationship was Carl Leighton of Wildwood Capital.
According to a new agreement, Rockland Immunochemicals will market established technologies including the CellCountEZ®, OxPhos™, RadDose™ and the Intracellular ThiolEZ™ assays.
George Prendergast, PhD, President and CEO of LIMR stated: “We have been very pleased with our partnership with Rockland and are looking forward to continued success within this expanded relationship.”
"LIMR's independent research encompassing cancer and inflammation elegantly enhances Rockland's antibody portfolio and technology platform. It is my belief that the new products included in our expanded licensing and commercialization agreement will enhance our ability to bring unique scientific opportunities to the global research community," commented James Fendrick, President and CEO of Rockland Immunochemicals.
Included in the additional product lines will be the CellCountEZ® assay measuring metabolically active cells while simultaneously quantifying cell death to determine cell viability, cell toxicity or cellular proliferation.
The OxPhos™ assay is capable of determining the cellular glutathione recycling capacity in tissue culture as well as that of whole blood, thus providing insight into oxidative stress during the aging process, antioxidant levels upon delivery of chemotherapy regime and toxicology.
The RadDose™ assay is used for the measurement of ionizing radiation dose rates, while the Intracellular ThiolEZ™ assay is capable of determining total intracellular thiols, including glutathione and cysteine, as a means of investigating the aging, oxidative stress, antioxidant, chemotherapy response and toxicology processes.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE